GCCL Signs New Drug Development MOU with Global CRO GemPharmatech
On July 22, GCCL, the clinical trial sample analysis organization of the GC Green Cross Group, announced that it had signed a memorandum of understanding (MOU) on July 21 with global non-clinical CRO (contract research organization) GemPharmatech for collaboration in new drug development services.
Gempahmatech North America CEO Dr. Brandy Wilkinson, GCCL CEO Jo Gwan-gu, Gempahmatech Founder and Chairman Dr. Xiang Gao. GCCL
View original imageThe signing ceremony was attended by Jo Gwangoo, CEO of GCCL; Dr. Xiang Gao, founder and chairman of GemPharmatech; Dr. Brandy Wilkinson, CEO of GemPharmatech North America; and other company representatives.
Through this agreement, the two companies will discuss linking new drug development services from the non-clinical stage through to clinical trials, and will jointly pursue the discovery of business opportunities and marketing collaboration. The approach will connect GCCL's expertise in central lab operations, bioanalysis, and sample management for clinical stages, with GemPharmatech's non-clinical in vivo efficacy testing and portfolio of disease and genetically engineered animal models.
The companies plan to advance joint marketing and networking activities both online and offline, primarily in Korea, the United States, and China. In particular, the United States is expected to be a key strategic market for the partnership, as it serves as a hub for pharmaceutical and biotech innovation and there is a growing demand for integrated services that span from non-clinical to clinical development phases.
Dr. Xiang Gao, chairman of GemPharmatech, stated, "Both companies share the common goal of accelerating new drug development for patients around the world. By connecting GemPharmatech's non-clinical capabilities with GCCL's clinical-stage expertise, we will help customers continue development seamlessly from early research through clinical trials."
Dr. Brandy Wilkinson, CEO of GemPharmatech North America, added, "In the U.S. market, there is a continuous increase in demand for faster and more integrated development pathways from the drug discovery stage to clinical entry. Through this collaboration, we will support our customers in maintaining high continuity between non-clinical and clinical development stages as they advance their programs."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jo Gwangoo, CEO of GCCL, remarked, "This agreement marks an opportunity for GCCL to expand its global collaboration network and provide integrated development support services to pharmaceutical and biotech clients. By linking GemPharmatech's non-clinical capabilities and GCCL's clinical-stage sample analysis expertise, we will help our clients move efficiently and seamlessly from early-stage research to clinical development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.